ArticlePharmaceuticals (Basel, Switzerland)2020
RETRACTED: Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity.
Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- RETRACTED: Ibrahim et al. Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Design, synthesis, andRSC advances · 2026Article
- Recent Advances in Microtubule Targeting Agents for Cancer Therapy.Molecules (Basel, Switzerland) · 2025Review
- Synthesis of novel quinoline-thiazolobenzimidazolone hybrids as anticancer agents through caspase-dependent apoptosis.Future medicinal chemistry · 2025Article
- Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer.Molecular diversity · 2024Article
- Exploring the antitumor potential of novel quinoline derivativesRSC advances · 2024Article
- A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization.International journal of molecular sciences · 2022Review
- Advances in antitumor research of CA-4 analogs carrying quinoline scaffold.Frontiers in chemistry · 2022Review
- New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3Pharmaceuticals (Basel, Switzerland) · 2021Article
- Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Design, Synthesis, and Antipoliferative Activities of Novel Substituted Imidazole-Thione Linked Benzotriazole Derivatives.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
- Retracted
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
A novel series of quinoline derivatives of combretastatin A-4 incorporating rigid hydrazone and a cyclic oxadiazole linkers were synthesized and have demonstrated potent tubulin polymerization inhibitory properties. Many of these novel derivatives have shown significant antiproliferative activities in the submicromolar range. The most potent compound,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.